For instance, osimertinib, a third-generation tyrosine kinase inhibitor, prolonged progression-free survival (PFS) to 18.9 months in patients with lung adenocarcinoma with the epidermal growth factor receptor (EGFR) common mutation [6]. Here, EGFR is linked to lung adenocarcinoma.